A Closer Look at Benefits of Tricuspid Edge-to-Edge Repair

After T-TEER, 75% of patients were alive and well at 1 year with a suggestion of a survival benefit.

In the randomized TRILUMINATE Pivotal trial, tricuspid transcatheter edge-to-edge repair (T-TEER) with an investigational device did not reduce death or heart failure hospitalization at 1 year compared with medical therapy alone in patients with severe tricuspid regurgitation; however, patient-reported health status was improved (NEJM JW Cardiol Mar 6 2023 and N Engl J Med 2023; 388:1833). This prespecified analysis of trial results further examined the timing and magnitude of health status benefits.

Among 332 randomized patients, results were as follows:

The Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ-OS) increased from a baseline of 56 points (range, 0–100; higher=better) by an average of 14 and 5 points in the T-TE…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)